Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Atypical central neurocytoma

F Söylemezoglu1, B W Scheithauer, J Esteve

  • 1Department of Pathology, University Hospital, Zürich, Switzerland.

Journal of Neuropathology and Experimental Neurology
|May 1, 1997
PubMed
Summary

Central neurocytomas with a high MIB-1 labeling index (MIB-1 LI) over 2% show increased vascular proliferation and a higher relapse rate. These findings support classifying high MIB-1 LI neurocytomas as atypical central neurocytomas, WHO grade II.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expression of leukemia inhibitory factor in craniopharyngioma.

Endocrine pathology·2016
Same author

Localization of vascular endothelial growth factor in nontumorous human pituitaries.

Endocrine pathology·2016
Same author

Invasive thymoma metastatic to the cavernous sinus.

Surgical neurology international·2013
Same author

Tumefactive demyelination and glioblastoma: a rare collision lesion.

Clinical neuropathology·2011
Same author

Dysembryoplastic neuroepithelial tumor and calcifying pseudoneoplasms of the neuraxis: a collision of two seizure-associated lesions.

Clinical neuropathology·2011
Same author

Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis.

Journal of neuro-oncology·2010

Area of Science:

  • Neuro-oncology
  • Pathology
  • Molecular Biology

Background:

  • Central neurocytomas are rare tumors of the central nervous system.
  • Assessing the proliferative potential is crucial for predicting tumor behavior and patient outcomes.

Purpose of the Study:

  • To evaluate the proliferative potential of central neurocytomas using the MIB-1 labeling index (MIB-1 LI).
  • To correlate MIB-1 LI with histopathological features, specifically vascular proliferation.
  • To compare disease-free survival between central neurocytoma groups based on MIB-1 LI and propose a new classification.

Main Methods:

  • Analysis of 36 central neurocytoma biopsy samples.
  • Determination of MIB-1 LI as a measure of growth fraction.
  • Correlation analysis with vascular proliferation.

Related Experiment Videos

  • Kaplan-Meier survival analysis to assess disease-free survival.

    • Main Results:

    • The mean MIB-1 LI was 2.8% (range 0.1-8.6%).
    • Central neurocytomas with MIB-1 LI > 2% (39% of cases) showed a significant correlation with vascular proliferation (p = 0.0006).
    • Patients with MIB-1 LI > 2% had a significantly higher relapse rate (63% vs. 22%) over 150 months (p = 0.0068).

    Conclusions:

    • A MIB-1 LI > 2% in central neurocytomas is associated with vascular proliferation and poorer disease-free survival.
    • The term 'atypical central neurocytoma' is proposed for tumors with MIB-1 LI > 2%, aligning with WHO grade II classification.
    • MIB-1 LI serves as a valuable prognostic marker for central neurocytomas.